On September 14, 2026, Ascendis Pharma announced it will regain exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. This follows the termination of its collaboration agreement with Novo Nordisk A/S, previously announced in November 2024. Under the agreement terms, all licenses granted to Novo Nordisk for these indications revert to Ascendis, and neither party has continuing financial obligations to the other. Ascendis Pharma is a biopharmaceutical company focused on developing transformative therapies for serious diseases.

On September 14, 2026, the Board of Directors authorized a new share repurchase program allowing the company to buy back up to $400 million of ordinary shares. Purchases may be executed through open market transactions, privately negotiated deals, block trades, accelerated share repurchases, or 10b5-1 plans at management's discretion based on market conditions and share price. The program does not mandate a specific number of shares and can be modified, suspended, or terminated without notice. Ascendis Pharma A/S is a biotechnology company focused on developing therapies for rare diseases.

On September 9, 2026, Ascendis Pharma announced Week 52 data from the open-label sentinel cohort of its reACHin Trial for TransCon CNP (navepegritide) in infants with achondroplasia. Treatment demonstrated stabilization or improvement in foramen magnum stenosis, with a mean sagittal diameter increase of +3.15 mm and no decompression surgeries. Linear growth benefits included a mean annualized growth velocity of 9.9 cm/year and a supine length Z-score change of +0.42. The drug was generally well-tolerated with no treatment-related adverse events leading to discontinuation. Ascendis Pharma A/S is a biopharmaceutical company focused on developing therapies for rare diseases.

On August 31, 2026, Ascendis Pharma entered a binding term sheet for a global settlement and license agreement with BioMarin Pharmaceutical to resolve all litigation. BioMarin granted Ascendis a non-exclusive, worldwide, royalty-bearing license to research, develop, manufacture, and commercialize navepegritide-related products without restriction, while waiving certain regulatory rights and dismissing proceedings. In exchange, Ascendis agreed to dismiss its claims against BioMarin and pay royalties equal to 20% of net sales in the United States and 18% in the European Union, South Korea, and Brazil from the first commercial sale through May 20, 30. This agreement secures Ascendis' freedom to operate for its navepegritide pipeline. The company operates in the biotechnology industry, focusing on developing therapies for rare diseases.

Ascendis Pharma A/S reported second quarter 2026 financial results with total revenue increasing to €339 million from €158 million in the prior year period, driven by a 105% year-over-year surge in product revenue to €315 million. Product sales included €252 million for YORVIPATH, €55 million for SKYTROFA, and €8 million for YUVIWEL. The company achieved an operating profit of €220 million, significantly improving from a €53 million loss in the same period last year, aided by a one-time cash receipt of €158 million from the sale of a Rare Pediatric Disease Priority Review Voucher. Additionally, Ascendis settled all outstanding $575 million convertible senior notes through conversion and was added to multiple Russell U.S. Indexes following its market capitalization growth. The company operates in the biopharmaceutical industry, developing therapies using its TransCon technology platform for rare endocrine diseases.